| Ytd | 216.62% | |
| 1y | 148.14% |
| Open | 51.20 | Prev Close | 50.75 | Low | 48.20 | High | 51.84 | Mkt Cap | 3.48B |
| Vol | 1.06M | Avg Vol | 1.38M | EPS | -1.64 | P/E | N/A | Forward P/E | -20.88 |
| Beta | 0.40 | Short Ratio | 3.89 | Inst. Own | 89.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 42.32 | 200-d Avg | 29.39 | 1yr Est | 62.89 |
ELVN News
Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the p
Jones Trading analyst Boris Peaker maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and ra
This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gain
Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction
US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Indus
Stitch Fix (SFIX) reported better-than-expected financial results, causing its shares to jump 15.8%.
Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ: ELVN), a clinical-stage biopharmaceutic
Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrad
Stifel analyst Dara Azar initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rati
Enliven will host a webcast conference call on June 11, at 8:30 a.m. ETBURLINGAME, Calif., June 3, 2